Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming ...( -- Patients suffering from a range...)

-- Patients suffering from a range of debilitating illnesses, such as

spinal cord injury, cerebral palsy, optic nerve hypoplasia, multiple sclerosis and ataxia stand to benefit from a new laboratory, established with a Chinese Government grant. Such a facility will put China at the forefront of the global race to engineer and reprogram human stem cells for

positive medical benefit.

SHENZHEN, Nov. 13 /Xinhua-PRNewswire/ -- Beike Biotechnology, ( http://www.beikebiotech.com ), the leader in stem cell applications for medical treatment, has announced that it has formally established a world- class laboratory facility for the research of cell reprogramming and gene engineering, through a joint agreement with the Shenzhen Graduate School of China's renowned Tsinghua University. The lab will conduct research on stem cells, the nuclear transfer and reprogramming of cells, monoclonal antibodies known as "magic bullets" for treating disease and other scientifically exciting cell engineering innovations. The aim of the lab is to establish a global research hub that will hopefully someday provide breakthroughs in the way medical science seeks to treat diseases like cancer, Parkinson's, and many other debilitating ailments.

"We are already helping thousands of patients with our current umbilical cord stem cell treatments, but this ultra high-tech lab will bring us even closer to our goal of helping millions of patients improve their quality of life and will ensure that we have more advanced products in our pipeline four to five years out," said Beike Biotech's Chairman, Dr. Sean Hu. Detailed patient experiences with videos of patients that have been treated with Beike's umbilical cord treatment can be found on China's stem cell news website: http://www.stemcellschina.com .

The 1,200 square meter laborato
'/>"/>